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Venous thromboembolism produces chronic sequelae in
the legs and occasional immediate mortality due to pul-
monary embolism. Because it occurs in certain high risk
situations (for example, after surgery) its prevention is
a practical proposition. This has been attempted using
many different approaches. Administration of low dose
heparin with or without dihydroergotamine to enhance
venous return has been one of the most widely tested
regimens. There is little doubt that this can prevent, in
many patient groups, postoperative deep venous throm-
bosis and fatal pulmonary embolism, with a low inci-
dence of adverse reactions. Some particularly high risk
postoperative patient groups (for example, those
undergoing hip surgery) warrant more aggressive mea-
sures to prevent thrombosis. Surveys have shown that
increasing use is being made of this approach, and it is
hoped that all surgeons will adopt a policy that will
reduce postoperative venous thrombosis and pulmonary
embolism.
Deep vein thrombosis of the legs is a common age-related
phenomenon manifested by focal intravascular coagulation
in which the mechanism is obscure, the clinical recognition
elusive, the recurrence rate high and mortality related to
pulmonary embolism unpredictable. Apart from the im-
mediate risk to life, one must also consider the late sequelae
of extensive deep vein thrombosis-swelling of the legs,
varicose veins, ulceration and other trophic changes that
represent an equally distressing situation.
In this review, we discuss three aspects of management:
I) the prevention of the development of deep vein throm-
bosis and pulmonary embolism; 2) the treatment of venous
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A reduction in the incidence of venous thromboem-
bolism in large acute myocardial infarction is achieved
by low dose heparin, although early mobilization is im-
portant. In addition, many of the patients at risk merit
full dose anticoagulation to prevent intracardiac throm-
boembolism.
Established venous thrombosis is treated effectively
by intravenous heparin, followed by warfarin to keep
the prothrombin time at 1.2 to 1.5 times control, as
assessed using rabbit thromboplastin; most patients need
three months of treatment. Anticoagulation is warranted
for pulmonary embolism, with fibrinolytic therapy re-
served for patients with massive embolism and hemo-
dynamic compromise. Embolectomy is a heroic measure,
which may occasionally be lifesaving.
(J Am Coll CardioI1986;8:146B-158B)
thrombosis that has already occurred, to prevent progres-
sion, embolic sequelae or recurrence; and 3) the treatment
of pulmonary embolism itself.
Prevention of Venous Thrombosis
and Pulmonary Embolism, Particularly
in the Postoperative Period
It is often asked whether postoperative pulmonary em-
bolism is preventable and, furthermore, whether it is worth
preventing, because the mortality due to this complication
is extremely low and all prophylactic measures require su-
pervision, extra work, organization and vigilance. The data
presented in this section support the argument that not only
should this complication be prevented, but also several pro-
phylactic measures now available make prevention a prac-
tical proposition. Therefore, the most rational approach would
seem to be that of developing an effective method of pro-
phylaxis if the mortality due to pulmonary embolism is to
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be significantly reduced. To be adopted on a wide scale,
such a method must fulfill the following criteria: it must be
simple, safe and effective; it must be applicable to all types
of patients at risk of developing deep vein thrombosis and
it must cover the period of risk, which in surgical patients
has been shown to extend from the time of operation through
the first 7 to 10 postoperative days.
The efficacy of several prophylactic measures in pre-
venting death due to postoperative pulmonary embolism has
been assessed in numerous clinical trials, and in this first
section, we focus on this issue. Treatments tested have
included oral anticoagulants, dextran and low dose heparin.
However, low dose heparin has been most extensively in-
vestigated and at present is the most commonly used pro-
phylactic therapy for prevention of postoperative pulmonary
embolism. Therefore, the data from studies using this form
of prophylaxis are analyzed to answer the critical question:
Can death from pulmonary embolism be prevented?
Prevention of Deep Vein Thrombosis
in Surgical Patients
Low dose heparin prophylaxis. Early classical autopsy
studies established the connection between emboli in the
lungs and thrombi in the lower limbs. Therefore, it can be
argued that prevention of such thrombi should also lead to
reduction in the incidence of fatal pulmonary embolism. In
the early 1970s, many studies (1-34) demonstrated the ef-
ficacy of low dose subcutaneous heparin in preventing post-
operative deep vein thrombosis after nonorthopedic surgery
(Table I). These included 34 randomized clinical trials in-
volving 6,163 patients, and deep vein thrombosis was di-
agnosed by means of leg scanning with iodine-125-fibrin-
ogen uptake test. In 29 trials, there was a significant reduction
in the incidence of deep vein thrombosis in patients receiving
low dose heparin prophylaxis.
Few physicians would deny that venous thrombosis, al-
though very common, is generally a benign disease. With
the use of the iodine-125-fibrinogen test and phlebography,
it has been shown that in surgical patients, the majority of
thrombi form in the calf veins. A surprisingly high pro-
portion of these thrombi undergo spontaneous lysis. As dis-
cussed elsewhere in this symposium (35), in about 20% of
patients, these thrombi extend proximally from the calf into
the popliteal, femoral and iliac veins. In this group with
thrombosis extending proximally, pulmonary embolism oc-
curs in almost 50% of patients, only a very small proportion
of cases prove fatal (36). The effect of low dose heparin
prophylaxis on the extension of venous thrombosis was eval-
uated in four of the larger studies (10,15,25,37) of patients
undergoing elective abdominal surgery, which together in-
cluded more than 3,000 patients (Table 2). In 1,631 control
patients, thrombi were detected in 380, while extension of
thrombus occurred in 99 (6%). In contrast, of 1,485 patients
receiving heparin, thrombi were detected in 95 and exten-
sion occurred in only 9 (0.6%). The difference in the fre-
quency of extending thrombi between the two groups was
statistically significant, not only in the aggregate of these
four studies, but in each of the individual trials as well.
Combination of heparin and dihydroergotamine.
Changes in blood coagulation and stasis in the deep veins
of the lower limbs are both considered to be important
factors in the pathogenesis of deep vein thrombosis. It is,
therefore, logical to propose that prophylaxis might be better
achieved by methods that minimize or eliminate both of
these factors rather than by counteracting either factor alone.
Dihydroergotamine is a potent vasoconstrictor in humans
(3). Its site of action seems to be the capacitance vessels of
the limbs. Dihydroergotamine administered subcutaneously
has been shown to increase the velocity of venous flow in
the major veins of the legs by constricting the capacitance
vessels while exerting a negligible influence on resistance
vessels and capillary filtration (39). A single injection of
0.5 mg has been shown to increase the mean calf muscle
blood flow significantly, an effect that persists for up to 5
hours. It has also been shown that dihydroergotamine en-
hances the synthesis of prostaglandins, and this may affect
platelet function. Furthermore, several workers (40,41) have
also shown that administration of drugs that affect vascular
motility increases the release of plasminogen activator from
the vein wall. Therefore, it is possible that dihydroergota-
mine, by producing venoconstriction through its action on
alpha-adrenoreceptors of the vein wall, may enhance release
of plasminogen activator and, thus, increase fibrinolytic ac-
tivity.
Heparin-Dihydergot, a fixed combination of either 5,000
or 2,500 IU of heparin sodium with 0.5 mg of dihydroer-
gotamine mesylate, is available in single dose vials as the
sterile, lyophilized mixture. This preparation has been de-
veloped to overcome the physicochemical incompatibility
of the available parental formulations of both sodium and
calcium heparin with that of dihydroergotamine mesylate.
A number ofclinical trials (42-53) ofheparin-dihydroer-
gotamine in a variety of patient populations have been re-
ported (Table 3). The fibrinogen uptake test or venography
was used for diagnosis (42,43). These trials were random-
ized, with one exception. In general, the addition of di-
hydroergotamine reduced by a further 50% the already low-
ered incidence of deep vein thrombosis detected when heparin
alone was used. In addition, four clinical trials (44,50,54,55),
in which deep vein thrombosis was detected by the iodine-
125-fibrinogen test and venography performed in or-
thopedic patients, confirmed the superiority of the anti-
thrombotic effect of the combination compared with heparin
alone. Patients admitted to these four trials who received
heparin alone had approximately a 45% incidence of deep
vein thrombosis compared with 20% among those receiving
the combination. There was no recognized difference in the
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Table 1. Effectiveness of Low Dose Hepann in the Prevention of Postoperative Deep Vein Thrombosls*
Frequency of ThrombosIs (%)
No. of LD
Study Authors (reference) Pallent PopulatIOn Pts. Controls Hep. Value
Abernethy and Hartsuck (I) General surgery 125 5 6 NS
Ansay et al. (2) General surgery 50 63 26 <0.05
Ballard et al. (3) Gynecology 110 29 4 <0.01
BergqvIst and Hallbook (4) General surgery 97 27 13 <0.05
Cerrato et al. (5) Neurosurgery 100 34 6 <0.005
Clarke-Pearson et al. (6) Gynecology, malignancy 185 12 15 NS
Coe et al (7) Urology 52 25 21 NS
Covey et al. (8) General surgery lOS 10 8 NS
Gallus et al (9) General surgery 209 IS I <0.001
Gallus et al. (10) General surgery 820 16 4 <0.05
Gordon-Smith et al. (II) General surgery ISO 42 14t <0003
8t <0.001
Groote Schuur Hospital (l2l Abdominal surgery 199 27 12 <0.007
Gruber et al (13) General surgery 194 36 13 <0.005
Hedlund and Blomback (14) Urology 59 46 21 NS
Intemallonal Multicentre Trial (15) General surgery 1292 25 8 <0.005
Jackaman et al. (16) Thorax surgery 183 51 28 <0.005
Joffe (17) General surgery 120 51 9 <0.0005
Kakkar et al. (18) General surgery 78 42 8 <0.001
Kettunen et al. (19) General surgery 200 41 8 <0001
Kraytman et al. (20) General surgery 50 63 26 <0.05
Kutnowsky et al. (21) Urology 47 36 <) <005
Lahnborg et al. (22) Abdommal surgery 112 20 5 <0.05
Lawrence et al. (23) Abdominal surgery 242 17 7 <005
Muill-Unit Controlled Tnal (24) General surgery 160 43 IS <0.05
Gynecology 55 14 0 <0.05
ThoraCIC surgery 38 44 IS <0.05
NicolaIdes et al. (25) General surgery 251 24 I <0.001
Plante et al. (26) General surgery 108 21 7 <0.05
Rem et al. (27) General surgery, urology 178 36 13 <0.001
Rosenberg et al. (28) General surgery 154 44 7 <0.001
Sebeseri et aI. (29) Urology 65 58 12 <0.01
Strand et aI. (30) General surgery 100 20 6 <0.05
Tabemer et aI. (31) Gynecology 57 23 6 <0.05
Tomgren and Forsberg (32) Abdominal surgery 124 33 165 <0.05
Williams (33) Abdommal surgery 44 33 0 <0.02
Wu et aI. (34) Abdominal surgery 88 14 0 <0.01
*The iodine-125-fibnnogen test was used to detect deep venous thrombOSIS. tin total, three doses of low dose heparin. tLow dose hepann for 5
days LD Hep. = low dose heparin; NS = not significant; Pts. = patients.
amount of operative or postoperative blood loss in the two
treatment groups, although the heparin concentration in plasma
was significantly higher in the patients who received the
combined treatment (44).
Low molecular weight heparin prophylaxis. Com-
mercially available heparin consists of a family of straight
chain anionic polysaccharides, more specifically, glycosa-
minoglycan sulfate esters of highly variable molecular weight,
averaging 9,000 to 15,000 daltons, but ranging from 3,000
to 40,00 daltons. Heparin has the ability to form a complex
with antithrombin III, but only a specific portion of the
heparin in clinically used prep<lrations binds strongly to
antithrombin III, as discussed by Wessler and Gitel (56)
elsewhere in this symposium. With affinity chromatography
on purified matrix-bound antithrombin, heparin can be di-
vided into one fraction (about one-third of the total amount)
with a high affinity for antithrombin III and high antico-
agulant activity, and one virtually inactive fraction with a
low affinity for antithrombin 1Il (57,58). According to these
observations, low molecular weight heparin should possess
antithrombotic properties, possibly without causing exces-
sive bleeding.
The efficacy and safety ofa low molecular weight heparin
fraction in preventing postoperative venous thromboem-
bolism was assessed in a double-blind, randomly allocated
trial and in an "open" study reported together, (59). Of
395 patients included in the double-blind trial, 199 received
unfractionated calcium heparin, and 196 received the low
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Table 2. Effect of Low Dose Heparin on the Proximal ExtensIOn of Thrombi in the Popliteal,
Femoral and Iliac Veins in Patients Undergoing Abdominal Surgery
Control Group Hepann Group
No. of No with No. of No. with
Reference Pts. DVT Extension Pts. DVT Extension
Corrigan et al. (36) 434 121 29 320 23 I
Nicolaides et al. (25) 122 29 9 128 II 0
Gallus et al. (10) 408 66 12 412 13 3
Kakkar et al. (15) 667 164 49 625 48 5
Total 1,631 380 (23.3%) 99 (6%) 1,485 95 (5.79%) 9 (0.6%)
DVT = deep vein thrombow,; Pts. = patients.
molecular weight heparin fraction. The data were analyzed
on an "intention to treat" basis, The two groups were well
matched for risk factors that could predispose to the de-
velopment of venous thrombosis. Fifteen (7.5%) of 199
patients receiving unfractionated heparin and 5 (2.5%) of 196
patients in the low molecular weight heparin group devel-
oped deep venous thrombosis (p < 0.05), There was no
significant difference between the two groups in terms of
incisional or total blood loss during surgery, postoperative
drainage or wound hematoma formation. Of 910 patients
included in the open study who received a single injection
of low molecular weight heparin every day, 30 (3.2%) died
during the postoperative period; in none of the autopsy pa-
tients were pulmonary emboli detected. Thirty-one patients
(3.4%) developed isotopic deep venous thrombosis; 27 (2.9%)
were receiving prophylaxis at the time this was diagnosed.
Thirty-six patients (3.9%) developed wound hematoma; 25
(12.4%) of these were among the 201 patients undergoing
surgery for gynecologic conditions, and II (1.5 %) were
among the 709 patients having general abdominal surgery.
This difference was statistically significant (p < 0.001).
Thus, the results of a double-blind trial indicate that a single
daily injection of 1,850 activated partial thromboplastin time
units (7,500 antifactor Xa units) of a low molecular weight
heparin is efficacious in preventing postoperative deep ve-
nous thrombosis. The findings of the open study (59) suggest
that this regimen also provides an effective prophylaxis against
postoperative major pulmonary embolism.
Prevention of Fatal Pulmonary Embolism
Because fatal pulmonary embolism is uncommon, a large
scale multicenter trial is needed to assess potential differ-
ences in mortality between treated and control patients. The
most comprehensive trial of low dose heparin prophylaxis
against fatal pulmonary embolism is from King's College
Hospital, London, and is known as the International Mul-
ticentre Trial (15). The results of this study published in
1975 provide a foundation for current recommendations
concerning postoperative prophylaxis. The study was car-
Table 3. Prophylactic Antithromboembolic Effect of Dihydroergotamine Alone or in
Combination With Low Dose Heparin*
No. of
% With Thrombosis
Reference Patient Population Pts. Control DHE LDH DHE-LDH
Buttermann et al. (41) General surgery 106 35 9
Fey et al. (42) General surgery 148 57 33
Kakkar et al. (43) Abdominal surgery 197 20 4 6
Elective surgery 100 52 20
Koppenhagen et al. (44) General surgery 253 14 6.5
GynecologIc surgery
Kunz et al. (45) Gynecologic surgery 178 15 7
Lahnborg (46) Hip fracture 210 39 20 16
Morris and Hardy (47) ElectIve hip surgery 81 56 22 4
Muhe et al (48) General surgery 150 44 24
Sagar et al. (49) Elective hip surgery 82 69 32 16
Schondorf and Weber (50) Elective hip surgery 108 15 4
Sechas et al. (51) General surgery, urologic 80 12 2
Stamatakls et al. (52) General surgery 100 16 4 4
*The iodine-125-fibrinogen test was used to detect deep vein thrombosis. DHE = dihydroergotamine;
LDH = low dose heparin; PIs. = patIents.
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ried out in 28 centers in a randomized controlled design.
Eligible patients were older than 40 years of age and were
scheduled to undergo elective major surgery. Those
undergoing emergency surgery and those receiving anti-
coagulant therapy were excluded.
Patients in the treatment group received 5,000 units of
subcutaneous calcium heparin 2 hours preoperatively and
every 8 hours thereafter for 7 days. If a patient was still
confined to bed at the end of this period, the therapeutic
regimen was continued until the patient became ambulatory.
Control patients did not receive any specific prophylaxis.
Randomization provided treatment and control groups that
were well matched for baseline characteristics. Each cen-
ter's pathologist was asked to record the causes of death.
Uniform criteria were established for determining that pul-
monary embolism was the cause of death (that is, if necropsy
revealed massive fresh emboli in the pulmonary trunk the
main pulmonary artery or at least two lobar arteries and if
no other possible cause of death was found).
Analysis ofthe results in the first 2,000 patients indicated
a substantially greater benefit from heparin than had been
envisaged at the planning stage. The incidence of fatal pul-
monary embolism in the control group was approximately
1% rather than 0.5% as was originally thought. Entrance to
the trial was, therefore, closed when 4,471 patients had
been admitted. Three hundred ten patients were excluded
from the analysis for several reasons, leaving 4,121 patients
in whom the protocol had been correctly followed (2,076
in the control group and 2,045 in the heparin group). The
two groups were well matched for age, sex, weight, blood
group and other factors that could predispose to the devel-
opment of venous thromboembolism. One hundred eighty
patients (4.4%) died during the postoperative period, 100
in the control group and 80 in the heparin group. Of the
patients who died, 72% from the control group and 66%
from the heparin group underwent necropsy. Sixteen pa-
tients in the control group and two in the heparin group
were found to have died as a result of acute massive pul-
monary embolism (p < 0.005). In addition, emboli found
at necropsy in six patients in the control group and three in
the heparin group were considered either contributory to
death or an incidental finding, since death in these patients
was attributed to other causes. The findings were again
significant (p < 0.005) when all cases of pulmonary em-
bolism were considered together. One of the 350 patients
excluded from the trial also died from pulmonary embolism.
This patient had received heparin. Even when this patient
was included in the analysis, the results were still highly
significant (p < 0.005). In addition, 24 patients in the con-
trol group and 8 in the heparin group were treated for clin-
ically suspected pulmonary embolism; this difference was
statistically significant (p < 0.0005). Deep venous throm-
bosis was detected at necropsy in 24 patients in the control
group and 6 in the heparin group (p < 0.005). Thirty-two
patients in the control group and 11 in the heparin group
developed deep venous thrombosus that was confirmed by
venography (p < 0.005). The difference in the number of
patients requiring treatment for deep venous thrombosus or
pulmonary embolism, or both, in the two groups was sig-
nificant (p < 0.005).
No therapeutic trial has escaped some form of adverse
criticism; this is true of all the trials involving an evaluation
of antithrombotic agents. Of the criticisms leveled against
this study, only three are considered to be pertinent to an
evaluation of the accuracy of the conclusions. 1) Was the
autopsy rate high enough to avoid imbalances between au-
topsy and nonautopsy patients? 2) To what extent did errors
in pathologic interpretation influence the results? 3) To what
extent could bias have influenced the results? Responses to
these questions have been adequately summarized by Sherry
(60). The autopsy rate of 70% is high enough to exclude
imbalance as a likely source of error. As for the second
question, some error in pathologic interpretation is possible,
but considering the competence of the pathologists, the error
must be relatively small compared with the striking differ-
ences between the groups. Finally, as to the question of
bias, this is of no influence when death is used as the end
point.
Subsequently, a report of Gruber et al. (61) from one of
the participating centers in the International Multicentre Trial
was issued. As already indicated, the major end point of
the trial and fatal pulmonary embolism diagnosed at au-
topsy. Pulmonary embolisms was considered to have caused
the patient's death if the necropsy revealed massive fresh
emboli in the pulmonary trunk, the main pulmonary artery
or at least two lobar arteries and if no other cause of death
was found. However, Gruber et al. claimed that multiple
peripheral emboli may also cause death and, hence, should
be considered fatal. Using this revised criterion for fatal
pulmonary embolism, they reported that in 6 of 94 patients
who received heparin, the cause of death was acute pul-
monary embolism. These data were inconsistent with their
previous report (62) and with the study design that was
returned to the multicenter trial center. Therefore, a second
International Multicentre Trial was organized by these au-
thors, using the same protocol as in the first trial. A total
of 4,352 patients were admitted to this prospective random-
ized trial, which was designed to compare the prophylactic
efficacy of dextran 70 and low dose heparin against fatal
pulmonary embolism after elective operation for general,
orthopedic, urologic and gynecologic diseases. The results
of this study were reported in January 1980 (63). Of 3,984
patients correctly admitted to the study, 1,993 were allo-
cated to receive dextran and 1,991 to receive low dose
heparin. Of 75 patients who died within 30 days after op-
eration, 38 had been given dextran and 37 had been given
low dose heparin. Necropsy was performed in 33 and 32
of these cases, respectively. The pulmonary arteries were
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Table 4. Causes of Death in Patients With
Nonfatal Pulmonary Emboli
Complications of Low Dose Heparin Prophylaxis
Hemorrhage. The risk of hemorrhage is the main lim-
itation to the routine use of anticoagulants for the prevention
dissected down to small segmental vessels, Cases of pul-
monary embolism were divided into three groups: I) those
in which no other cause of death was found, 2) those in
which pulmonary embolism was considered to be a con-
tributory cause of death, and 3) those in which pulmonary
embolism was regarded as incidental. Embolism found at
autopsy was considered to be the sole cause of death in only
3 of 1,991 patients who had received heparin, Another three
patients in the heparin group had pulmonary embolism as
a contributory cause of death, Thus, the total incidence of
pulmonary embolism demonstrated at autopsy was 6 of 1,991
patients. These figures are the same as reported by us in
1975 (15).
Furthermore, a statistical overview (undertaken by the
Clinical Trial Service Unit, Radcliffe Infirmary, Oxford,
U.K.) of the randomized controlled trials of low dose hep-
arin prophylaxis where mortality from pulmonary embolism
was not the main end point supports the results ofthe original
multicenter trial. Correspondence with the investigators
yielded cause-specific mortality by allocated treatment for
all randomized patients (Table 4). An overview of these
results indicated 29 control-allocated pulmonary embolism
deaths and only 6 treatment-allocated pulmonary embolism
deaths (p < 0.001). In addition, nonfatal pulmonary em-
bolism was moderately reduced, as was death from causes
other than pulmonary embolism. In most of these trials, it
might have been fairly obvious which patients were receiv-
ing active treatment, a factor that could have biased the
assessment of nonfatal pulmonary embolism and, to a lesser
extent, whether deaths were due to pulmonary embolism,
although total mortality was also significantly reduced
(p < 0.03).
No. of death,
No of necrop"es
Causes of death
Pulmonary embolus
Pneumonia
MyocardIal infarctIOn
Peritonitis
Pulmonary edema
Carcinomatosis
Sepllcemla
Hepatic failure
Renal failure
Hemorrhage
Other,
Control
100
72
16
13
13
9
3
5
4
I
a
5
3
Heparin
80
53
2
II
7
7
5
5
3
2
2
4
5
of thromboembolic disease in surgical patients. One definite
criterion for evaluating this risk is the frequency of wound
hematoma formation.
Two studies (10,44) of a large number of patients re-
ported a significant difference between the number of pa-
tients receiving heparin and the number of their control
counterparts who developed wound hematoma. However,
a recent double-blind study by Kiil et al. (64) failed to con-
firm such a difference. The reason for this discrepancy arises
from the fact that in the International Multicentre Trial (15)
and the study reported by Gallus et aL (10), heparin was
administered every 8 hours, whereas it was administered by
Kiil et al. (64) every 12 hours (64). Similar results have
been reported by other workers. It seems that there is a
small but definite risk of bleeding when an 8 hour regimen
is used, but not when a 12 hour regimen is followed.
A much higher incidence of bleeding complications has
been observed in some of the studies (65) reported in the
United States. This difference could be due to several fac-
tors. Plasma heparin levels after subcutaneous administra-
tion depend not only on the molecular weight of the heparin
preparation, but also on the type of heparin salt used and
the standard that is used by the manufacturers for the cal-
ibration of heparin. Unfortunately, two standards are used.
In the United States, heparin is calibrated according to the
USP unit, which in the past has been 15% more potent than
the international unit (lU) established by the World Health
Organization. Most European studies have been carried out
using heparin calibrated in international units. The differ-
ence between the two standards is relatively small, but to-
gether with other factors likely to affect heparin absorption,
it may give rise to sufficiently higher levels to produce
serious bleeding. Currently, the difference between the two
units is less. The USP unit is now only 6 to 7% more potent
than the international unit.
Another important factor that might have contributed to
the higher incidence of bleeding complications reported from
the United States relates to the concentration of heparin
solution used. The use of multidose vials is inconvenient
and wasteful and, at times, may lead to bleeding due to the
accidental administration of large amounts of heparin. Am-
pules made specially for prophylactic use are now available.
They contain 5,000 units of either the calcium or sodium
salt of heparin in 0.2 ml aqueous solution. The widespread
use of such specially prepared ampules has certainly reduced
the frequency of bleeding complications.
Ecchymosis at the injection site. This complication has
also been observed more frequently when the sodium salt
of heparin has been used. Such differences could be due to
the fact that the sodium and calcium salts of heparin behave
differently when administered subcutaneously. A compar-
ative trial (66) showed that the calcium salt caused signif-
icantly less ecchymosis at the site of injection than did the
sodium salt. Of 266 subcutaneous injections (133 each of
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sodium heparin and calcium heparin), sodium heparin caused
local bruising greater than 0.5 cm in diameter in 7%, less
than 0.5 cm in 47% and none at all in 46%, whereas calcium
heparin produced local bruising over 0.5 cm in diameter in
3%, less than 0.5 cm in 22% and no bruising in 75% (p <
0.001). Pain was rarely reported. When present, it was not
significantly different in patients receiving the two heparin
preparations and was not related to the formation or size of
hematomas.
Adoption of Low Dose Heparin Prophylaxis
Low dose heparin. The value of low-dose heparin in
the prophylaxis of postoperative deep vein thrombosis can
no longer be seriously disputed. For prophylactic therapy
to be widely adopted, it must be easily administered, readily
available, of low cost and, above all, of minimal risk. The
basic question is the benefiUrisk ratio. There is now good
reason to believe that the potential benefits of prophylactic
low dose heparin far outweigh the risk of hemorrhage. A
significant reduction in the incidence of fatal pulmonary
embolism, for example, can be achieved at the cost of a
2.5% increase in the incidence of postoperative bleeding,
largely in the form of wound hematoma formation.
Two recent surveys suggest that low dose heparin pro-
phylaxis is now being used more widely. All 236 clinics in
Sweden dealing with general, urologic, orthopedic and gy-
necologic surgery were sent a questionnaire concerning their
policy about prophylaxis against thromboembolism (67);
94% replied, and 76% claimed to use some kind of pro-
phylaxis. Prophylactic methods in current use varied among
the four specialties surveyed; replies were received from 87
to 100% of the clinics surveyed. Several pharmacologic
agents were used as prophylaxis against postoperative ve-
nous thromboembolism. These included oral anticoagulants,
low dose heparin, acetylsalicylic acid and the combination
of dihydro ergotamine and heparin. Low dose heparin was
used in 78% of the general surgery patients, 54% of the
urologic surgery patients, only 39% of the orthopaedic sur-
gery patients and 69% of the gynecologic surgery patients.
In a second survey (68), in the United Kingdom, 752
orthopedic and 663 general surgeons were sent a question-
naire asking how they attempted to prevent venous throm-
boembolism. The survey concerned prophylaxis offered
routinely to elderly patients with hip fractures, patients
undergoing elective hip replacement arthroplasty and pa-
tients undergoing major abdominal and thoracic operation.
Approximately 70% of those questioned replied. The gen-
eral surgeons returned 521 questionnaires, for an effective
response rate of78%. The orthopedic surgeons returned 605
questionnaires, and 47 surgeons did not complete that part
of the questionnaire that dealt with patients who had hip
fractures, either because their practice did not include such
patients or because they were involved in clinical trials of
prophylactic agents. Similarly, 59 surgeons did not com-
plete the section concerning patients undergoing elective
hip replacement arthroplasty. Thus, the effective response
rate was 74% for hip fractures and 73% for hip replace-
ments. The survey showed that more general surgeons pro-
vide routine prophylaxis than do their orthopaedic col-
leagues. The difference was attributable mainly to the
popularity of low dose heparin among general surgeons.
That low dose heparin prophylaxis is effective in general
surgical patients has been detailed widely, and the consensus
seems to be in its favor. The safety and simplicity of the
method were persuasive factors and accounted for the fact
that 25% of all the general surgeons who replied use low
dose heparin routinely as the sole method of prophylaxis.
Oral anticoagulants. The routine use of oral antico-
agulants has been recommended for nearly 20 years for the
prevention of venous thromboembolic complications. In the
Netherlands, for instance, more than 60% of surgeons rou-
tinely use this form of prophylaxis. Yet in the United King-
dom. none of 515 surgeons undertaking general abdominal
surgery indicated that they use oral anticoagulants compared
with 128 (24.8%) who reported that they use low dose
heparin routinely as the sole method of prophylaxis. This
trend surely must be considered as a major breakthrough
when one considers that the objective evidence of the ef-
fectiveness of this form of prophylaxis has been accumulated
only during the past few years.
Reasons for not using prophylaxis: role of the clini-
cian. The survey undertaken by Morris (68) suggests that
published evidence concerning the prevention of venous
thromboembolism has had only a limited influence on sur-
gical practice in the United Kingdom, and the question has
arisen as to whether the published evidence that supports
the prophylaxis is convincing. To those who find it is, the
inaction of the surgeons who do not employ prophylaxis
may be regarded as negligence. However, those who are
familiar with the published data and do not provide pro-
phylaxis may choose not to do so for two reasons. First,
there is a great discrepancy between the ubiquity of venous
thromboembolism and the relative infrequency with which
it causes death. Second, an individual surgeon, no matter
how extensive his or her personal practice, will never rec-
ognize the success of the prophylactic action, yet will in-
variably be reminded of each failure. In view of such cir-
cumstances, what should be the role of the practicing clinician?
The published evidence and the clinical experience with low
dose heparin prophylaxis should now be used to influence
the methods used by surgeons for preventing fatal pulmo-
nary embolism occurring after operation.
Prevention of venous thromboembolism in myo-
cardial infarction. The incidence of deep vein thrombosis
in the legs in acute myocardial infarction ranges from 17 to
38% (69,70), as detected by fibrinogen uptake, which is
similar to the incidence in patients after surgery, but higher
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than that in patients with chest pain but no myocardial in-
farction. Clinically obvious pulmonary emboli occurred in
5% of patients who were not treated with anticoagulants in
the Veterans Administration Cooperative Clinical Trial (71)
of anticoagulants in acute myocardial infarction (0.6% of
cases were fatal) and in 5% in the similar British Medical
Research Council Study (72). Deep venous thrombi form
early after infarction (50% or more are detectable within 3
days). The incidence is higher in patients with heart failure,
shock or prolonged immobility (73) and probably in older
patients.
Heparin. Full anticoagulation significantly reduces the
incidence of deep venous thrombi in the legs to 6% or less
and reduces the incidence of clinical pulmonary embolism
from 5 to 6% to 2% (71,72). In three randomized trials (70,
74, 75) in patients with acute myocardial infarction, low
dose heparin reduced the incidence of deep vein thrombosis
from 23% of 145 control patients to 4% of 138 treated
patients (who had no increased bleeding). Low dose heparin
was started within 12 to 18 hours of the onset of symptoms
of acute myocardial infarction and was continued for ap-
proximately 10 days. The low dose regimen reduced the
rate of venous thrombosis even in higher risk subgroups
with heart failure and reduced the propagation of thrombus
to the ileofemoral veins, which is important in preventing
pulmonary embolism. These studies were performed before
current early mobilization schedules were practiced, and it
is possible that the risk/benefit ratio is now different.
Present recommendations. The first therapeutic goal
for the prevention of deep vein thrombosis and pulmonary
embolism in patients with acute myocardial infarction should
be early mobilization. Immediate subcutaneous administra-
tion of low dose heparin (5,000 U every 8 to 12 hours)
should be reserved for the high risk patients with one or
more of the following characteristics: age older than 70
years, large acute myocardial infarction, previous myo-
cardial infarction, heart failure or shock, necessity for pro-
longed immobilization (>3 days), previous deep vein
thrombosis or pulmonary emboli or obesity. At least some
of these patients will merit full anticoagulation to prevent
intracardiac thromboembolism as discussed in the review
by Adams et al.(76).
Treatment of Established Deep
Vein Thrombosis
Successful immediate treatment of deep vein thrombosis
should prevent extension of the thrombus, prevent embolism
to the lungs and restore patency to the venous circulation,
while maintaining normal venous valve function and, thus,
protect the patient against the postphlebitic syndrome. No
controlled trial has specially addressed the use of heparin
in deep vein thrombosis (77). However, its value in the
prevention of deep vein thrombosis and its role in the treat-
ment of pulmonary embolism, which is almost always de-
rived from thrombi in the deep veins of the leg and pelvis,
strongly support its clinical efficacy. Heparin does not dis-
solve formed thrombi, although it may stimulate endoge-
nous fibrinoloysis. In situations where an additional effect
beyond the natural fibrinolytic system is necessary (that is,
in the presence of threatened mechanical complications),
pharmacologic fibrinolysis may be valuable, as discussed
next.
Heparin. The pharmacology and administration of hep-
arin have been dealth with elsewhere in the symposium.
Two issues shoud be recapitulated here. Heparin can be
given by either continuous infusion or intermittent injection.
Although studies comparing the two methods of adminis-
tration have given conflicting results, two of the studies
(78,79) clearly indicated that a continuous infusion was
associated with a considerable reduction in bleeding com-
plications. Thus, this should be used where possible. The
role of larger dose subcutaneous heparin as an alternative
to infusion warrants further investigation.
Monitoring therapy. The second issue is of monitoring
therapy. In animal experiments, a minimal level of heparin
of 0.4 units/ml is needed to interrupt an established throm-
botic process. Further support for the need for a minimal
level of anticoagulation comes from a prospective study (80)
in which recurrence of venous thrombosis was associated
with an activated partial thromboplastin time of less than
1.5 times control. The evidence that maintaining the acti-
vated partial thromboplastin time at less than 2.5 times
control will significantly reduce hemorrhage is not strong.
However, this should be attempted, although often without
great success, because the dose-response curve for heparin
varies considerably from patient to patient.
Which patient should be treated? Patients with throm-
bus extending above the popliteal vein have a high incidence
of postphlebitic syndrome and of pulmonary embolism (81),
and anticoagulation is certainly warranted. There has been
uncertainty, however, in cases where thrombosis is confined
to the calf veins (82). Minor thrombi in calf veins seldom
cause major pulmonary emboli, and the development of the
risks of postphlebitic syndrome is low, particularly if the
popliteal vein is not occluded (81). The use of anticoagu-
lation in such cases has, therefore, been questioned. The
situation has been clarified for symptomatic calf vein throm-
bosis. In a recent study (83), phlebography was used to
define a population of patients in whom thrombosis was
present but in whom it did not extend into the popliteal vein,
although all were symptomatic. After an initial course of
heparin, the patients were randomized to receive compres-
sive stockings and warfarin for 3 months (to give a pro-
thrombin time of 1.4 to 1.9 times control; international
normalized ratio of 2.5 to 4.2) or compressive stockings
alone. Recurrences, which often extended into proximal
veins and were associated with pulmonary embolism in one
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case, were much more common in the nonanticoagulated
group. In asymptomatic cases detected by postoperative sur-
veillance, the balance of risk and benefit remains at present
unclear (77). Patients with superficial thrombophlebitis do
not warrant anticoagulation; treatment with nonsteroidal anti-
inflammatory agents is usually adequate. However, occa-
sional patients with recurrent symptoms may respond to
anticoagulants.
Duration of heparin therapy. Little information is
available regarding the optimal duration of therapy with
heparin. Although therapy with heparin is generally rec-
ommended for 7 to 10 days, this may not interrupt the
thrombotic process in all patients. For example, in a study
comparing low dose herapin with warfarin in the mainte-
nance therapy of deep venous thrombosis, Hull et al (84)
found that 9 of 35 patients in the low dose heparin group
developed new episodes of thromboembolism after 14 days
of intravenous heparin. Thus, we would recommend 7 to
10 days of therapy for most patients, less in those with a
remedial thrombus-provoking factor and perhaps more for
those with large thrombi or a persistent predisposing factor
(for example, cancer) (85).
Warfarin. The study of Hull et al. (84) clearly showed
that continued full anticoagulation is needed after heparin.
Although this can be achieved with warfarin or with adjusted
dose subcutaneous heparin (86), the latter less convenient
for the patient. Treatment with warfarin is adequate to pre-
vent recurrent deep venous thrombosis if the prothrombin
time is prolonged from 1.2 to 1.5 times normal (using rabbit
thromboplastin; an international normalized ratio of 2.0 to
3.0). If the traditional intensity of anticoagulation is used,
with a prothombin time of 1.5 to 2.0 times control, the risk
of hemorrhage is unacceptably high (85). During the ini-
tiation of warfarin therapy, it can be safely overlapped with
heparin, warfarin being started 4 days before heparin is to
be discontinued to ensure that its anticoagulant effect is fully
established (87). Warfarin can still be monitored by the
prothrombin time during heparin therapy by discontinuing
heparin for 6 hours before checking the patient. Indeed, if
a continuous infusion of heparin is used and the activated
partial thromboplastin time is within the range of 1.5 to 2.5
times control, the prothrombin time remains a reliable guide
to the effect of warfarin without stopping the heparin (88).
Most authorities feel that anticoagulant treatment with
warfarin should continue for at least 6 months if thrombus
extends above the popliteal vein or if pulmonary embolism
has occurred. If a predisposing condition (for example, im-
mobility) has resolved, a shorter course of treatment may
suffice, while a persistent thrombotic predisposition may
warrant longer-term treatment (74,85), as does recurrent
thrombosis. Patients with calf vein thrombosis may not need
more than 12 weeks of therapy.
Fibrinolytic therapy. In patients with extensive deep
vein thrombosis, it is suggested that fibrinolytic therapy is
associated with a marked reduction in the incidence of the
postphlebitic syndrome, particularly if treatment is given
soon after the development of symptoms. The incidence of
the postphlebitic syndrome in these patients with extensive
thrombosis receiving streptokinase is about 10%, while it
may be as high as 90% in patients treated with heparin alone
(89). Furthermore it is also claimed that completely normal
venograms are seen in about 60% of patients treated with
streptokinase intravenously over 3 to 5 days in standard
doses and in only about 11 % of patients treated with heparin
(90). However, recent results of long-term studies clearly
demonstrate that thrombolytic therapy does not prevent the
postphlebitic syndrome. Deciding which patients may ben-
efit from fibrinolysis is difficult. Younger patients in whom
the risk of hemorrhage is lower and those with clear evidence
of proximal involvement to the thigh probably do so. Pa-
tients with a short history « 3 days) improve the most,
although treatment of longer established thrombi may be
successful. It is difficult to justify the use of a fibrinolytic
agent with its increased risk of hemorrhage in the absence
of definitive proof of the diagnosis. Thus, venography or a
similar investigation should be performed in all patients in
whom fibrinolytic therapy is considered.
In summary. patients with deep venous thrombosis, in-
cluding those with symptomatic calf vein thrombosis, should
receive heparin for 7 to 10 days overlapped by warfarin to
prolong the prothrombin time by 1.2 to 1.5 times normal.
Therapy should be continued for 6 months in most patients
(perhaps less in those with predisposing conditions that have
resolved and probably for 12 weeks in patients with calf
vein thrombosis). Fibrinolytic therapy should be considered
in those patients with proximal venous obstruction who are
not at risk of hemorrhage.
Treatment of Pulmonary Embolism
Heparin Therapy
Almost all pulmonary emboli arise in the deep veins of
the leg or pelvis, as discussed by Hirsh et al. (91) earlier
in this symposium. In many cases, the treatment for pul-
monary embolism does not differ from that described for
thrombosis in the deep veins (that is, immediate anticoag-
ulation with heparin followed by maintenance therapy with
warfarin. This was shown in one study (92) performed in
the 1960s, in which 35 patients with pulmonary embolism
were randomized to receive anticoagulants or no therapy.
Five of 19 untreated patients died, while I of 16 in the
anticoagulated group died, the cause of death being only
indirectly related to pulmonary embolism. A further 38 pa-
tients received anticoagulants, with one death, not due to
pulmonary embolism. This policy was examined by further
studies (93,94), which although not controlled, provided
confirmatory evidence of the efficacy of heparin. Further-
more, in a group of patients with pulmonary embolism in
whom anticoagulant therapy was believed to be strongly
contraindicated (95), the mortality was very high.
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This evidence strongly supports the efficacy of heparin
in the prevention of progression of disease and further em-
bolism in venous thromboembolism (96). Its use in cases
of pulmonary embolism is clearly indicated. Dose regimens
will, in most cases, be similar to those used for deep vein
thrombosis as outlined, but the clearance of heparin is ac-
celerated by large pulmonary embolism (97). Thus, in this
setting, larger doses of the drug are needed, in some cases
up to 60,000 to 75,000 units over the first 24 hours.
Fibrinolytic Therapy
Although therapy with heparin may stimulate fibrinolysis
slightly and may reverse the bronchoconstrictor response to
pulmonary embolism (85), definitive therapy is needed if
sufficient thrombus is present in the pulmonary circulation
to embarrass significantly the patient's overall hemodynamic
status. Thus, patients with massive embolism, right heart
failure and hypotension have up to a 30 to 40% hospital
mortality, and it is these patients who are most likely to
benefit from definitive therapy, with either fibrinolytic agents
or surgery.
To define the role of thrombolytic therapy, the National
Heart, Lung, and Blood Institute performed two controlled
trials comparing urokinase and heparin (Phase I. Urokinase
Pulmonary Embolism Trial) (98) and subsequently uroki-
nase and streptokinase (Phase II, Urokinase-Streptokinase
Pulmonary Embolism Trial) (99) in the treatment of pul-
monary embolism. These two trials, in which 327 patients
with angiographically confirmed pulmonary embolism were
studied, showed the following: 1) greater resolution of pul-
monary emboli with fibrinolytic therapy than with heparin,
as assessed by pulmonary angiography before and after treat-
ment; 2) greater improvement of the abnormal hemody-
namic status of the right heart and pulmonary circulation
with fibrinolytic therapy than with heparin; 3) greater re-
perfusion of the original perfusion defects with lytic therapy
than with heparin, as assessed by repeated perfusion lung
scans; 4) maximal clot resolution and general improvement
in patients with the largest pulmonary emboli; and 5) no
difference in the relatively low, (8 to 9%) mortality rate
between patients given heparin and those given thrombolytic
therapy.
Although mortality was not reduced in these two studies,
most deaths from pulmonary embolism occur in the first
hour after symptoms, and many of the patients who die
would not be included in studies of the type described. In
view of the benefits noted in terms of pulmonary perfusion
and cardiac output in these two studies, however, it seems
likely that fibrinolytic therapy, together with intensive sup-
portive care, may save lives.
A further potential advantage to the use of fibrinolysis
is a reduction in long-term effects. Histologic changes in
pulmonary arteries and arterioles occur in patients treated
with heparin alone after pulmonary embolism. Lung scans
4 months after embolism reveal that normal findings return
in only about 20% of patients treated with heparin over this
period (100). A more recent study (101) showed better im-
provement in pulmonary capillary blood volume and per-
fusion at both 2 weeks and I year in a streptokinase-treated
group when compared with a heparin-treated group. If fi-
brinolytic agents are to be used, pulmonary angiography
should almost always be performed because the higher risk
of bleeding with fibrinolytic therapy than with heparin (98)
makes precise diagnosis mandatory. Although fibrinolytic
therapy is clearly indicated when there is severe hemody-
namic compromise, its value in less severe cases relatively
minor for the prevention of long-term changes in pulmonary
vascular resistance (101) is unclear when weighed against
the inconvenience and risk of thrombolysis.
Surgical Therapy
Embolectomy. The role of surgical embolectomy is lim-
ited. The operation can be performed closed or open on
cardiopulmonary bypass, the latter being preferable if ad-
equate time is available. Occasional successes are seen,
although mortality is very high. It should almost certainly
be used only as a last resort, perhaps being restricted to
patients with cardiac arrest (96). Percutaneous pulmonary
embolectomy has been used with a special catheter (102),
the tip of which consists of a suction cup with which the
embolism is removed. Experience is limited with this de-
vice. Its use has generally been followed by placement of
a caval occlusion device, particularly the Greenfield filter.
Inferior vena cava interruption. A few patients are
seen in whom anticoagulation and particularly fibrinolytic
therapy is contraindicated (for example, patients recovering
from intracranial hemorrhage, neurosurgery or recent major
trauma). The management of life-threatening pulmonary
embolism in these patients may be aided by interruption of
the vena cava to prevent further embolism. Recurrent em-
bolism despite adequate anticoagulation is also an indication
for this procedure. The inferior vena cava can be interrupted
by a variety of techniques of surgical plication, while the
percutaneous transvenous insertion of filters has become
more popular recently. The Greenfield filter and the Mobin-
Uddin umbrella are two devices in current use. Recurrent
thromboembolism from such a device may occur, and se-
quelae in the lower body as a result of venous hypertension
are not uncommon (103). Anticoagulation has been used in
patients in whom the device has been placed for recurrent
embolism to prevent thrombosis on the device.
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